Overview
- Corvus said it plans to begin a Phase 2 atopic dermatitis trial in Q1 2026, targeting about 200 patients across three dosing arms and a placebo group.
- Soquelitinib’s safety profile remained favorable with no new signals, no severe or serious adverse events, and only Grade 1–2 events that required no dose changes.
- Biomarkers supported pharmacologic activity, including dose‑dependent reductions in serum IL‑4 in later cohorts and IL‑5 decreases observed as early as day 8, with lower IL‑17 and TARC levels also reported.
- In cohort 4, clinical responses deepened through day 56 with widening separation from placebo, and two placebo patients experienced disease flares versus none on soquelitinib.
- Shares of Corvus (CRVS) jumped about 140% to $19.28 on volume of roughly 30.79 million following the data release, far above the average session volume of about 1.33 million.